While there are many reports demonstrating an elevated NF-κB activity in prostate cancer, there were hardly any clinical attempts to inhibit that signaling pathway therapeutically, most likely because NF-κB is also crucial for immune cell functions, which are considered essential for tumor immune surveillance—and which should obviously not be hampered. This evidence concerns the gene NFKB1 and prostate carcinoma.